ArticleFrontiers in genetics2026
Retrospective analysis of preoperative serum tumor marker levels and their correlation with pathological characteristics and prognosis in cervical cancer patients.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the relationship between the levels of preoperative serum tumor markers SCC-Ag, CEA, and CA125 and pathological characteristics in cervical cancer patients, and to analyze their predictive value for prognosis. Methods: A retrospective analysis was conducted on clinical data from 82 patients with cervical cancer (cervical cancer group), 98 patients with benign cervical lesions (benign lesion group), and 80 healthy controls (healthy control group). Serum tumor marker levels were compared among the three groups to evaluate their diagnostic value for cervical cancer. Differences in tumor marker levels were assessed among cervical cancer patients with varying TNM stages, differentiation degrees, and pathological types. Pre-treatment tumor marker levels were also compared between patients with different prognoses. Results: Patients in the cervical cancer group exhibited significantly higher levels of SCC-Ag, CEA, and CA125 compared to the benign lesion and healthy control groups (P < 0.05). The AUCs of the three markers for diagnosing cervical cancer were 0.8338, 0.8379, and 0.8466, respectively (P < 0.0001). Tumor marker levels showed an increasing trend with advancing TNM staging and decreasing differentiation degree (P < 0.05). Patients with squamous cell carcinoma had significantly higher SCC-Ag levels, while those with adenocarcinoma had significantly higher CEA and CA125 levels (P < 0.05). At 2-year follow-up, the recurrence group exhibited significantly higher tumor marker levels before treatment compared to the non-recurrence group (P < 0.05). Conclusion: Serum levels of SCC-Ag, CEA, and CA125 are closely associated with the pathological characteristics of cervical cancer, demonstrating high diagnostic value. Pre-treatment tumor markers levels serve as important reference indicators for prognostic assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.